Are Sugar Free Energy Drinks Bad for You
Saaranen, M
#pharma #healthcare #obesity #innovation #strategy #GLP1 The drive for improvement will refine our pharmaceutical landscape
And people who stopped using the medications were significantly less optimistic about their benefits: Only about half of those who had used injectable weight-loss drugs in the past said they were effective, compared with nearly three-quarters of those who were actively using the treatments
[21] [22] Regarding GLP-1 medications and lymphoedema , there is currently insufficient evidence to recommend their use specifically for this condition
Pedersen has also received payment for medical education lectures and speakers bureaus from AstraZeneca, Bausch, Eli Lilly, Novo Nordisk, Janssen, Boehringer Ingelheim, Sanofi, Merck, Abbott, Dexcom, HLS, Bayer, and Pfizer, and has received travel support from AstraZeneca, Bausch, Eli Lilly, Novo Nordisk, Beohringer Ingelheim, Abbott, and Dexcom